Menopausal genuine stress urinary incontinence treated with conjugated estrogens plus progestogens.
ABSTRACT The aim of the study was to investigate clinically and urodynamically the effects of hormonal replacement in the treatment of genuine stress urinary incontinence in postmenopausal females.
Clinical and urodynamic variables of 30 postmenopausal women with genuine stress urinary incontinence were evaluated after 3 months' treatment with conjugated estrogens plus progestogens. Urodynamic evaluations were performed in all patients before and after treatment.
Forty-six percent of the patients treated medically were judged to be cured and 43% were judged to be markedly improved. Maximum urethral closure pressure, maximum cystometric capacity and mean flow were significantly increased. Residual urine and diurnal and nocturnal voluntary micturition were markedly decreased (P < 0.05).
We conclude that hormone replacement in the form of conjugated estrogens plus progestogens results in the clinical and urodynamic improvement of genuine stress urinary incontinence in postmenopausal women.
Journal of Biotechnology 11/2010; 150:207-207. DOI:10.1016/j.jbiotec.2010.09.019 · 2.88 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: To determine the vaginal pH level that correlates with elevated parabasal cells in vaginal smears. Postmenopausal women presenting to a gynecology office for routine annual and incontinence examinations were studied prospectively. Women were excluded if they had vaginal infections or pelvic organ prolapses past the hymen. pH was measured and cytology smears made from the midvagina. A pathologist who was not aware of pH results evaluated the smears. Spearman rho was used to correlate pH and percentage of parabasal cells. Logistic regression was used to analyze the relationship between pH and increased parabasal cells in vaginal smears. Predictive values were used to select a pH level as a cutoff point to predict increased parabasal cells. Seventy-four women were enrolled and 70 completed the study. The correlation coefficient between pH and percentage of parabasal cells was 0.6 (P < .001). Logistic regression showed association of pH with 20% or more parabasal cells (P < .001). Positive and negative predictive values for pH level above 6.0 as a predictor of 20% or more parabasal cells were 96.3% and 87.5%, respectively. The prevalence of elevated parabasal cells was 22.9%. Vaginal pH above 6.0 correlates with high levels of parabasal cells (20% or more) from the midvagina.Obstetrics and Gynecology 11/1999; 94(5):700-703. DOI:10.1016/S0029-7844(99)00384-1 · 4.37 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: We present a series of 600 women with a mean age of 50.3 years (range: 49 to 61 years) and a mean age at menopause of 49.4 years (range: 47 to 55 years).Parity oscillated between 1 and 4 children, with a mean parity of 1.8 children.A protocol was applied by a gynecologist in all women. In addition to age and parity, the protocol included the use of hormone replacement therapy (HRT) and whether the women had urinary incontinence in the previous year, or currently had this disorder, whether stress urinary incontinence, urge urinary incontinence or mixed urinary incontinence.There were 270 postmenopausal women, representing 45% of the sample. Of these, 151 (55.9%) reported having, or having had, some urinary incontinence of different types and quantities during the previous year. The most frequent type was stress urinary incontinence (56.9%), followed by urge urinary incontinence (29.5%), and mixed urinary incontinence (13.6%).Only slightly more than one fourth of the patients (27.8%) were using HRT at the time of the consultation. Of these, 58.7% complained of urinary incontinence compared with 41.3% of women not reporting this disorder. Among patients using HRT and reporting urinary incontinence, 56.9% had stress urinary incontinence, 29.5% reported urge urinary incontinence and the remaining 13.6% reported mixed urinary incontinence.The most important finding of the present study is that HRT does not seem to protect against urinary incontinence.Clínica e Investigación en Ginecología y Obstetricia 12/2007; 34(6). DOI:10.1016/S0210-573X(07)74514-8